Pre-Open Stock Movers 12/16: (JBL) (HZNP) (TXMD) Higher; (AGIO) (VCEL) (FNSR) Lower (more...)
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) 19.6% LOWER; announced that it is no longer developing its second pyruvate kinase-R (PKR) kmspico download free , AG-519, and withdrew its investigational new drug (IND) application yesterday following a verbal notification of a clinical hold from the U.S. Food and Drug Administration (FDA). These decisions do not affect the Companys ongoing global Phase 2 study (DRIVE PK) for AG-348, a novel, first-in-class activator of both wild-type (normal) and mutated PKR enzymes. Agios is advancing AG-348 into pivotal development as the first potential disease-modifying treatment for pyruvate kinase (PK) deficiency.
Vericel Corporation (NASDAQ: VCEL) 15.7% LOWER; announced the pricing of its previously announced underwritten public offering of 6,200,000 shares of its common stock, offered at a price to the public of $2.75 per share
Jabil Circuit (NYSE: JBL) 10.6% HIGHER; reported Q1 EPS of $0.69, $0.05 better than the analyst estimate of $0.64. Revenue for the quarter came in at $5.1 billion versus the consensus estimate of $4.91 billion. GUIDANCE: Jabil Circuit sees Q2 2017 EPS of $0.35-$0.57, versus the consensus of $0.46. Jabil Circuit sees Q2 2017 revenue of $4.2-4.5 billion, versus the consensus of $4.36 billion.
Horizon Pharma (NASDAQ: HZNP) 9% HIGHER; entered into a rebate agreement with Express Scripts (NASDAQ: ESRX), which secures formulary status for DUEXIS, VIMOVO, PENNSAID 2% w/w and RAYOS® Delayed-Release Tablets. Mizuho Securities upgraded Horizon from Neutral to Buy.
TherapeuticsMD (NYSE: TXMD) 7.6% HIGHER; Cantor Fitzgerald initiated coverage with an Overweight rating and a price target of $34.00
Finisar Corporation (NASDAQ: FNSR) 5% LOWER; announced the pricing of its previously announced offering of $500,000,000 aggregate principal amount of its 0.50% Convertible Senior Notes due 2036 in a private placement.
Pioneer Energy Services Corp (NYSE: PES) 5% HIGHER; Goldman Sachs upgraded from Neutral to Buy with a price target of $7.50.
Nordstrom (NYSE: JWN) 3.6% LOWER; JPMorgan downgraded from Neutral to Underweight with a price target of $48.00 (from $55.00).
Trina Solar Limited (NYSE: TSL) 3.5% HIGHER; announced that the Company's shareholders voted in favor of, among others, the proposal to authorize and approve (i) the previously announced agreement and plan of merger dated August 1, 2016 by and among Fortune Solar Holdings Limited, Red Viburnum Company Limited and the Company, pursuant to which Merger Sub will be merged with and into the Company with the Company continuing as the surviving company as a wholly-owned subsidiary of Parent after the merger, (ii) the plan of merger required to be filed with the Registrar of Companies of the Cayman Islands, substantially in the form attached to the Merger Agreement, and (iii) any and all transactions contemplated by the Merger Agreement, including the Merger.
Oracle (NYSE: ORCL) 2.2% LOWER; sees Q3 adjusted EPS in constant currency of $0.61-$0.64 vs the consensus of $0.64. Revenue is seen up 3%-5% in constant currency.
Gilead Sciences (Nasdaq: GILD) 1.8% LOWER; must pay Merck (NYSE: MRK) $2.54 billion for using a patented invention as the basis for its blockbuster drugs Sovaldi and Harvoni to treat Hepatitis C, according to Bloomberg, citing a federal jury in Delaware.
Las Vegas Sands (NYSE: LVS) 1.5% HIGHER; Goldman Sachs initiated coverage with a Buy rating and added the stock to its Conviction Buy List with a price target of $68.
Merck (NYSE: MRK) 1.2% HIGHER; Gilead Sciences (Nasdaq: GILD) must pay Merck (NYSE: MRK) $2.54 billion for using a patented invention as the basis for its blockbuster drugs Sovaldi and Harvoni to treat Hepatitis C, according to Bloomberg, citing a federal jury in Delaware.
via source:http://www.streetinsider.com/Special+Reports/Pre-Open+Stock+Movers+1216%3A+(JBL)+(HZNP)+(TXMD)+Higher%3B+(AGIO)+(VCEL)+(FNSR)+Lower+(more...)/12350479.html













